

# Hans Prozesky

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2258026/publications.pdf>

Version: 2024-02-01

81  
papers

14,872  
citations

94415

37  
h-index

69246

77  
g-index

84  
all docs

84  
docs citations

84  
times ranked

13816  
citing authors

#	ARTICLE	IF	CITATIONS
1	Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. <i>New England Journal of Medicine</i> , 2019, 380, 2295-2306.	27.0	3,760
2	A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure. <i>New England Journal of Medicine</i> , 2001, 345, 1667-1675.	27.0	2,873
3	Empagliflozin in Heart Failure with a Preserved Ejection Fraction. <i>New England Journal of Medicine</i> , 2021, 385, 1451-1461.	27.0	2,143
4	Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. <i>New England Journal of Medicine</i> , 2020, 382, 1883-1893.	27.0	753
5	Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2017, 377, 723-732.	27.0	480
6	Risk Factors for Coronavirus Disease 2019 (COVID-19) Death in a Population Cohort Study from the Western Cape Province, South Africa. <i>Clinical Infectious Diseases</i> , 2021, 73, e2005-e2015.	5.8	405
7	Cardiovascular and Renal Outcomes with Efglenatide in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2021, 385, 896-907.	27.0	339
8	Life Expectancies of South African Adults Starting Antiretroviral Treatment: Collaborative Analysis of Cohort Studies. <i>PLoS Medicine</i> , 2013, 10, e1001418.	8.4	330
9	Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial. <i>Lancet Respiratory Medicine</i> , 2021, 9, 924-932.	10.7	218
10	Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups. <i>Circulation</i> , 2019, 140, 739-750.	1.6	211
11	Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness. <i>New England Journal of Medicine</i> , 2018, 379, 1118-1127.	27.0	205
12	Gender Differences in Survival among Adult Patients Starting Antiretroviral Therapy in South Africa: A Multicentre Cohort Study. <i>PLoS Medicine</i> , 2012, 9, e1001304.	8.4	199
13	Temporal changes in programme outcomes among adult patients initiating antiretroviral therapy across South Africa, 2002-2007. <i>Aids</i> , 2010, 24, 2263-2270.	2.2	198
14	Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial. <i>Circulation</i> , 2021, 144, 1284-1294.	1.6	195
15	Gender distribution of adult patients on highly active antiretroviral therapy (HAART) in Southern Africa: a systematic review. <i>BMC Public Health</i> , 2007, 7, 63.	2.9	160
16	Immunodeficiency at the Start of Combination Antiretroviral Therapy in Low-, Middle-, and High-Income Countries. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 65, e8-e16.	2.1	142
17	Difference in mortality among individuals admitted to hospital with COVID-19 during the first and second waves in South Africa: a cohort study. <i>The Lancet Global Health</i> , 2021, 9, e1216-e1225.	6.3	131
18	Rates and Predictors of Failure of First-line Antiretroviral Therapy and Switch to Second-line ART in South Africa. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 60, 428-437.	2.1	119

#	ARTICLE	IF	CITATIONS
19	A Dimorphic Fungus Causing Disseminated Infection in South Africa. <i>New England Journal of Medicine</i> , 2013, 369, 1416-1424.	27.0	118
20	Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis. <i>New England Journal of Medicine</i> , 2021, 385, 2325-2335.	27.0	112
21	Daprodustat for the Treatment of Anemia in Patients Not Undergoing Dialysis. <i>New England Journal of Medicine</i> , 2021, 385, 2313-2324.	27.0	108
22	Risk factors for COVID-19-related in-hospital mortality in a high HIV and tuberculosis prevalence setting in South Africa: a cohort study. <i>Lancet HIV</i> , 2021, 8, e554-e567.	4.7	105
23	Outcomes of antiretroviral treatment in programmes with and without routine viral load monitoring in southern Africa. <i>Aids</i> , 2011, 25, 1761-1769.	2.2	98
24	Outcomes of laboratory-confirmed SARS-CoV-2 infection in the Omicron-driven fourth wave compared with previous waves in the Western Cape Province, South Africa. <i>Tropical Medicine and International Health</i> , 2022, 27, 564-573.	2.3	94
25	Early Mortality and Loss to Follow-up in HIV-Infected Children Starting Antiretroviral Therapy in Southern Africa. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2010, 54, 524-532.	2.1	88
26	Clinical Characteristics, Diagnosis, Management, and Outcomes of Disseminated Emmonsiosis: A Retrospective Case Series. <i>Clinical Infectious Diseases</i> , 2015, 61, 1004-1012.	5.8	68
27	Effect of SGLT2 Inhibitors on Stroke and Atrial Fibrillation in Diabetic Kidney Disease. <i>Stroke</i> , 2021, 52, 1545-1556.	2.0	60
28	HIV Viral Load Suppression in Adults and Children Receiving Antiretroviral Therapy—Results From the leDEA Collaboration. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 76, 319-329.	2.1	58
29	Clinical Outcomes and Response to Vericiguat According to Index Heart Failure Event. <i>JAMA Cardiology</i> , 2021, 6, 706.	6.1	53
30	Incidence Rate of Kaposi Sarcoma in HIV-Infected Patients on Antiretroviral Therapy in Southern Africa. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 67, 547-554.	2.1	51
31	Twelve-year mortality in adults initiating antiretroviral therapy in South Africa. <i>Journal of the International AIDS Society</i> , 2017, 20, 21902.	3.0	50
32	Kaposi's Sarcoma in HIV-infected patients in South Africa: Multicohort study in the antiretroviral therapy era. <i>International Journal of Cancer</i> , 2014, 135, 2644-2652.	5.1	48
33	Where do HIV-infected adolescents go after transfer? Tracking transition/transfer of HIV-infected adolescents using linkage of cohort data to a health information system platform. <i>Journal of the International AIDS Society</i> , 2017, 20, 21668.	3.0	45
34	PROTEASE INHIBITOR RESISTANCE IN SOUTH AFRICAN CHILDREN WITH VIROLOGIC FAILURE. <i>Pediatric Infectious Disease Journal</i> , 2009, 28, 1125-1127.	2.0	44
35	Comparison of Kaposi Sarcoma Risk in Human Immunodeficiency Virus-Positive Adults Across 5 Continents: A Multiregional Multicohort Study. <i>Clinical Infectious Diseases</i> , 2017, 65, 1316-1326.	5.8	44
36	Monitoring the South African National Antiretroviral Treatment Programme, 2003-2007: the leDEA Southern Africa collaboration. <i>South African Medical Journal</i> , 2009, 99, 653-60.	0.6	44

#	ARTICLE	IF	CITATIONS
37	AIDS-Related Endemic Mycoses in Western Cape, South Africa, and Clinical Mimics: A Cross-Sectional Study of Adults With Advanced HIV and Recent-Onset, Widespread Skin Lesions. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx186.	0.9	41
38	Excess mortality associated with mental illness in people living with HIV in Cape Town, South Africa: a cohort study using linked electronic health records. <i>The Lancet Global Health</i> , 2020, 8, e1326-e1334.	6.3	40
39	Incidence of AIDS-defining and Other Cancers in HIV-positive Children in South Africa. <i>Pediatric Infectious Disease Journal</i> , 2016, 35, e164-e170.	2.0	38
40	HIV viral load as an independent risk factor for tuberculosis in South Africa: collaborative analysis of cohort studies. <i>Journal of the International AIDS Society</i> , 2017, 20, 21327.	3.0	38
41	A comparison of death recording by health centres and civil registration in South Africans receiving antiretroviral treatment. <i>Journal of the International AIDS Society</i> , 2015, 18, 20628.	3.0	37
42	CD4 count at antiretroviral therapy initiation and the risk of loss to follow-up: results from a multicentre cohort study. <i>Journal of Epidemiology and Community Health</i> , 2016, 70, 549-555.	3.7	34
43	Implementation of "Treat All" at adult HIV care and treatment sites in the Global leDEA Consortium: results from the Site Assessment Survey. <i>Journal of the International AIDS Society</i> , 2019, 22, e25331.	3.0	32
44	Age in antiretroviral therapy programmes in South Africa: a retrospective, multicentre, observational cohort study. <i>Lancet HIV</i> , 2015, 2, e368-e375.	4.7	29
45	Trends in CD4 and viral load testing 2005 to 2018: multicohort study of people living with HIV in Southern Africa. <i>Journal of the International AIDS Society</i> , 2020, 23, e25546.	3.0	27
46	Prioritising prevention strategies for patients in antiretroviral treatment programmes in resource-limited settings. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2010, 22, 775-783.	1.2	22
47	Immune Recovery After Starting ART in HIV-Infected Patients Presenting and Not Presenting With Tuberculosis in South Africa. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 63, 142-145.	2.1	21
48	CD4 Count Slope and Mortality in HIV-Infected Patients on Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 63, 34-41.	2.1	21
49	Influence of endpoint definitions on the effect of empagliflozin on major renal outcomes in the EMPEROR Preserved trial. <i>European Journal of Heart Failure</i> , 2021, 23, 1798-1799.	7.1	21
50	Tuberculosis and the risk of opportunistic infections and cancers in HIV-infected patients starting ART in Southern Africa. <i>Tropical Medicine and International Health</i> , 2013, 18, 194-198.	2.3	20
51	Kaposi Sarcoma Risk in HIV-Infected Children and Adolescents on Combination Antiretroviral Therapy From Sub-Saharan Africa, Europe, and Asia. <i>Clinical Infectious Diseases</i> , 2016, 63, ciw519.	5.8	20
52	The treatment gap for mental disorders in adults enrolled in HIV treatment programmes in South Africa: a cohort study using linked electronic health records. <i>Epidemiology and Psychiatric Sciences</i> , 2021, 30, e37.	3.9	20
53	The Impact of Delayed Switch to Second-Line Antiretroviral Therapy on Mortality, Depending on Definition of Failure Time and CD4 Count at Failure. <i>American Journal of Epidemiology</i> , 2020, 189, 811-819.	3.4	19
54	Determinants of Weight Evolution Among HIV-Positive Patients Initiating Antiretroviral Treatment in Low-Resource Settings. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 70, 146-154.	2.1	15

#	ARTICLE	IF	CITATIONS
55	Life expectancy trends in adults on antiretroviral treatment in South Africa. <i>Aids</i> , 2016, 30, 2545-2550.	2.2	15
56	Tuberculosis in Pediatric Antiretroviral Therapy Programs in Low- and Middle-Income Countries: Diagnosis and Screening Practices. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2015, 4, 30-38.	1.3	14
57	Zidovudine impairs immunological recovery on first-line antiretroviral therapy. <i>Aids</i> , 2013, 27, 2225-2232.	2.2	13
58	Characterizing the double-sided cascade of care for adolescents living with HIV transitioning to adulthood across Southern Africa. <i>Journal of the International AIDS Society</i> , 2020, 23, e25447.	3.0	13
59	Tenofovir in Second-Line ART in Zambia and South Africa. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 61, 41-48.	2.1	12
60	Has the phasing out of stavudine in accordance with changes in WHO guidelines led to a decrease in single-drug substitutions in first-line antiretroviral therapy for HIV in sub-Saharan Africa?. <i>Aids</i> , 2017, 31, 147-157.	2.2	12
61	Leadership and early strategic response to the SARS-CoV-2 pandemic at a COVID-19 designated hospital in South Africa. <i>South African Medical Journal</i> , 2020, 110, 463-465.	0.6	11
62	CD4+ T cell recovery during suppression of HIV replication: an international comparison of the immunological efficacy of antiretroviral therapy in North America, Asia and Africa. <i>International Journal of Epidemiology</i> , 2015, 44, 251-263.	1.9	10
63	Bartonella species as a cause of culture-negative endocarditis in South Africa. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2021, 40, 1873-1879.	2.9	9
64	Implementation and Operational Research. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 70, e110-e119.	2.1	8
65	Medication Side Effects and Retention in HIV Treatment: A Regression Discontinuity Study of Tenofovir Implementation in South Africa and Zambia. <i>American Journal of Epidemiology</i> , 2018, 187, 1990-2001.	3.4	8
66	Modified Duke/European Society of Cardiology 2015 clinical criteria for infective endocarditis: time for an update?. <i>Open Heart</i> , 2022, 9, e001856.	2.3	8
67	Recording of HIV Viral Loads and Viral Suppression in South African Patients Receiving Antiretroviral Treatment: A Multicentre Cohort Study. <i>Antiviral Therapy</i> , 2020, 25, 257-266.	1.0	7
68	Combined Antiretroviral Treatment Initiation During Hospitalization: Outcomes in South African Adults. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009, 51, 105-106.	2.1	6
69	Global temporal changes in the proportion of children with advanced disease at the start of combination antiretroviral therapy in an era of changing criteria for treatment initiation. <i>Journal of the International AIDS Society</i> , 2018, 21, e25200.	3.0	6
70	Clinical evolution, management and outcomes of patients with COVID-19 admitted at Tygerberg Hospital, Cape Town, South Africa: a research protocol. <i>BMJ Open</i> , 2020, 10, e039455.	1.9	6
71	Causes of infective endocarditis in the Western Cape, South Africa: a prospective cohort study using a set protocol for organism detection and central decision making by an endocarditis team. <i>BMJ Open</i> , 2021, 11, e053169.	1.9	6
72	Comparison of patients with severe COVID-19 admitted to an intensive care unit in South Africa during the first and second wave of the COVID-19 pandemic.. <i>African Journal of Thoracic and Critical Care Medicine</i> , 2021, 27, .	0.6	6

#	ARTICLE	IF	CITATIONS
73	Seasonal variations in tuberculosis diagnosis among HIV-positive individuals in Southern Africa: analysis of cohort studies at antiretroviral treatment programmes. <i>BMJ Open</i> , 2018, 8, e017405.	1.9	5
74	Tenofovir or zidovudine in second-line antiretroviral therapy after stavudine failure in southern Africa. <i>Antiviral Therapy</i> , 2013, 19, 521-525.	1.0	4
75	Extending Visit Intervals for Clinically Stable Patients on Antiretroviral Therapy: Multicohort Analysis of HIV Programs in Southern Africa. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 81, 439-447.	2.1	3
76	Brief Report: Assessing the Association Between Changing NRTIs When Initiating Second-Line ART and Treatment Outcomes. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 77, 413-416.	2.1	2
77	Regression discontinuity analysis demonstrated varied effect of Treat-All on CD4 testing among Southern African countries. <i>Journal of Clinical Epidemiology</i> , 2021, 140, 101-110.	5.0	1
78	Invasive fungal infections, other than <i>Candida</i> and <i>Cryptococcus</i> , from 2008 to 2011, at Tygerberg Hospital in the Western Cape, South Africa. <i>International Journal of Infectious Diseases</i> , 2012, 16, e323.	3.3	0
79	Early Surgery Determines Prognosis in Patients with IE: Outcome of Patients Managed by an Endocarditis Team - a Prospective Cohort Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
80	Incidence of Kaposi sarcoma in HIV-infected patients receiving antiretroviral therapy: A prospective multicohort study from southern Africa.. <i>Journal of Clinical Oncology</i> , 2011, 29, 1589-1589.	1.6	0
81	Record linkage augments cancer ascertainment in HIV cohorts in South Africa. <i>International Journal of Population Data Science</i> , 2017, 1, .	0.1	0